KR20220002860A - 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료 - Google Patents

피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료 Download PDF

Info

Publication number
KR20220002860A
KR20220002860A KR1020217022968A KR20217022968A KR20220002860A KR 20220002860 A KR20220002860 A KR 20220002860A KR 1020217022968 A KR1020217022968 A KR 1020217022968A KR 20217022968 A KR20217022968 A KR 20217022968A KR 20220002860 A KR20220002860 A KR 20220002860A
Authority
KR
South Korea
Prior art keywords
docetaxel
cancer
plasma levels
treatment
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217022968A
Other languages
English (en)
Korean (ko)
Inventor
제이콥 헨드릭 베이젠
요하네스 헨리쿠스 마티아스 셸렌스
Original Assignee
모드라 파마슈티컬스 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모드라 파마슈티컬스 비.브이. filed Critical 모드라 파마슈티컬스 비.브이.
Publication of KR20220002860A publication Critical patent/KR20220002860A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217022968A 2018-12-21 2019-12-18 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료 Ceased KR20220002860A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18215472 2018-12-21
EP18215472.4 2018-12-21
PCT/EP2019/086124 WO2020127606A1 (en) 2018-12-21 2019-12-18 Cancer treatment using docetaxel by controlling peak plasma levels

Publications (1)

Publication Number Publication Date
KR20220002860A true KR20220002860A (ko) 2022-01-07

Family

ID=64901394

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217022968A Ceased KR20220002860A (ko) 2018-12-21 2019-12-18 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료

Country Status (14)

Country Link
US (3) US20220079910A1 (enExample)
EP (1) EP3897610B1 (enExample)
JP (3) JP2022515249A (enExample)
KR (1) KR20220002860A (enExample)
CN (1) CN113543781A (enExample)
AU (2) AU2019410060A1 (enExample)
BR (1) BR112021012255A2 (enExample)
CA (1) CA3124316C (enExample)
CL (1) CL2021001638A1 (enExample)
ES (1) ES3026709T3 (enExample)
IL (1) IL284213A (enExample)
MX (2) MX2021007478A (enExample)
PE (1) PE20220250A1 (enExample)
WO (1) WO2020127606A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220002860A (ko) * 2018-12-21 2022-01-07 모드라 파마슈티컬스 비.브이. 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료
US20220071944A1 (en) * 2018-12-21 2022-03-10 Modra Pharmaceuticals B.V. Combination Treatment for Solid Tumors Using Docetaxel and a CYP3A Inhibitor
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
KR101544498B1 (ko) 2007-08-24 2015-08-17 스티칭 허트 네덜란드 칸커 인스티튜트 종양성 질환의 치료를 위한 조성물
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
WO2010020799A2 (en) 2008-08-22 2010-02-25 Slotervaart Participaties Bv Composition
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
KR20220002860A (ko) * 2018-12-21 2022-01-07 모드라 파마슈티컬스 비.브이. 피크 혈장 수준의 제어에 의한 도세탁셀을 사용하는 암 치료
US20220071944A1 (en) * 2018-12-21 2022-03-10 Modra Pharmaceuticals B.V. Combination Treatment for Solid Tumors Using Docetaxel and a CYP3A Inhibitor

Also Published As

Publication number Publication date
WO2020127606A1 (en) 2020-06-25
CL2021001638A1 (es) 2022-04-22
BR112021012255A2 (pt) 2021-09-28
EP3897610C0 (en) 2025-04-16
EP3897610B1 (en) 2025-04-16
EP3897610A1 (en) 2021-10-27
US20220079910A1 (en) 2022-03-17
PE20220250A1 (es) 2022-02-16
US20250312305A1 (en) 2025-10-09
AU2019410060A1 (en) 2021-08-05
US11571408B2 (en) 2023-02-07
US20220323399A1 (en) 2022-10-13
CN113543781A (zh) 2021-10-22
AU2023204682A1 (en) 2023-08-10
JP2023102787A (ja) 2023-07-25
JP2025094189A (ja) 2025-06-24
ES3026709T3 (en) 2025-06-12
CA3124316A1 (en) 2020-06-25
CA3124316C (en) 2023-07-04
JP2022515249A (ja) 2022-02-17
MX2025008270A (es) 2025-08-01
MX2021007478A (es) 2021-10-13
IL284213A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US20250312305A1 (en) Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels
JP2025094186A (ja) ドセタキセルおよびｃｙｐ３ａ阻害剤を用いる固形腫瘍の組み合わせ治療
KR20200026969A (ko) 치료제의 비경구 투여를 위한 조성물
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
US20070142346A1 (en) Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
CN114177299A (zh) 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途
EP4385507A1 (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
US20250144083A1 (en) Methods and compositions for treating cancer in taxane-resistant patients
McEntee et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs
HK40111479A (en) Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor
CN105228611B (zh) 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合
Mans et al. Phase I Study of Three-Times Daily Oral Etoposide in Patients with Refractory Solid Tumours.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601